ANI Pharmaceuticals, Inc.
ANIP
$95.20
-$0.15-0.16%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 747.40M | 674.07M | 614.38M | 555.46M | 538.95M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 747.40M | 674.07M | 614.38M | 555.46M | 538.95M |
| Cost of Revenue | 291.01M | 274.09M | 250.21M | 223.35M | 208.38M |
| Gross Profit | 456.39M | 399.98M | 364.17M | 332.11M | 330.58M |
| SG&A Expenses | 297.19M | 264.74M | 237.14M | 212.08M | 183.81M |
| Depreciation & Amortization | 84.52M | 75.94M | 67.73M | 60.33M | 59.78M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 726.59M | 659.40M | 599.66M | 533.56M | 490.77M |
| Operating Income | 20.81M | 14.67M | 14.72M | 21.90M | 48.19M |
| Income Before Tax | -14.75M | -27.56M | -22.21M | -7.50M | 35.51M |
| Income Tax Expenses | -4.54M | -6.51M | -3.69M | -412.00K | 8.49M |
| Earnings from Continuing Operations | -10.21 | -21.05 | -18.52 | -7.09 | 27.02 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -10.21M | -21.05M | -18.52M | -7.09M | 27.02M |
| EBIT | 20.81M | 14.67M | 14.72M | 21.90M | 48.19M |
| EBITDA | 105.33M | 90.60M | 82.45M | 82.23M | 107.97M |
| EPS Basic | -0.75 | -1.26 | -1.12 | -0.53 | 1.19 |
| Normalized Basic EPS | -0.03 | -0.25 | -0.22 | 0.07 | 0.87 |
| EPS Diluted | -0.77 | -1.27 | -1.13 | -0.55 | 1.17 |
| Normalized Diluted EPS | -0.04 | -0.25 | -0.22 | 0.06 | 0.86 |
| Average Basic Shares Outstanding | 78.29M | 77.78M | 77.27M | 76.83M | 76.31M |
| Average Diluted Shares Outstanding | 79.20M | 78.22M | 77.59M | 77.37M | 77.09M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -15.91% | -7.72% | -8.77% | -22.92% | 6.02% |